‹‹111››.
Chorfa A, Lazizzera C, Betemps D, et al. A variety of pesticides trigger in vitro α-synuclein accumulation, a key event in Parkinson’s disease.‹‹112››.
Dunnett SB, Bjorklund SBA. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease.‹‹113››.
Campdelacreu J. Parkinson disease and Alzheimer disease: environmental risk factors.‹‹114››.
Meng X, Munishkina LA, Fink AL, Uversky VN. Effects of various flavonoids on the α-synuclein fibrillation process.‹‹115››.
Strathearn KE, Yousef GG, Grace MH, Roy SA, et al. Neuroprotective effects of anthocyaninand proanthocyanidin-rich extracts in cellular models of Parkinson’s disease.‹‹116››.
Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson’s disease.‹‹117››.
Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease.‹‹118››.
Kukull WA. An apple a day to prevent Parkinson disease: reduction of risk by flavonoids.‹‹119››.
Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease.‹‹120››.
Serafini M, Testa MF, Villain D, et al. Antioxidant activity of blueberry fruit is impaired by association with milk.‹‹121››.
Jekanowski M. Survey says: a snapshot of rendering.‹‹122››.
Schepens PJ, Covaci A, Jorens PG, Hens L, Scharpé S, van Larebeke N. Surprising findings following a Belgian food contamination with polychlorobiphenyls and dioxins.‹‹123››.
Dórea JG. Vegetarian diets and exposure to organochlorine pollutants, lead, and mercury.‹‹124››.
Dórea JG. Fish meal in animal feed and human exposure to persistent bioaccumulative and toxic substances.‹‹125››.
Moser GA, McLachlan MS. The influence of dietary concentration on the absorption and excretion of persistent lipophilic organic pollutants in the human intestinal tract.‹‹126››.
Dórea JG. Vegetarian diets and exposure to organochlorine pollutants, lead, and mercury.‹‹127››.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease.‹‹128››.
Barranco Quintana JL, Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease and tea: a quantitative review.‹‹129››.
Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson’s disease in a large cohort of men and women.‹‹130››.
Nakaso K, Ito S, Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson’s disease model of SH-SY5Y cells.‹‹131››.
Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial.‹‹132››.
Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial.‹‹133››.
Grazina R, Massano J. Physical exercise and Parkinson’s disease: influence on symptoms, disease course and prevention.‹‹134››.
Chen J, Guan Z, Wang L, Song G, Ma B, Wang Y. Meta-analysis: overweight, obesity, and Parkinson’s disease.15. Как не умереть от ятрогенных причин
‹‹1››.
Pereira TV, Horwitz RI, Ioannidis JPA. Empirical evaluation of very large treatment effects of medical interventions.‹‹2››.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.‹‹3››.
Starfield B. Is US health really the best in the world?‹‹4››.
Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002.